Document Detail


The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease.
MedLine Citation:
PMID:  20522016     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Alzheimer's disease is a progressive, neurodegenerative disorder characterized by a devastating cognitive decline. The disease is identified pathologically by amyloid plaques composed of aggregated amyloid- peptide, neurofibrillary tangles composed of aggregated, hyperphosphorylated tau protein and neuron loss. While the disease was first described in 1906, transgenic mouse models for the study of Alzheimer's disease pathologies have only been available to scientists for fifteen years. Despite the generation of many different mouse models that develop amyloid plaques or neurofibrillary tangles, it has only been in recent years that mouse models demonstrating the two pathologies together have been made. Also, neuron loss has been difficult to achieve in many models. Most recently, several transgenic mouse lines have been generated that do demonstrate all three pathological characteristics of Alzheimer's disease: amyloid plaques, neurofibrillary tangles and neuron loss. This review will focus on the advances made in our understanding of Alzheimer's disease pathology using the transgenic mouse models. It will also discuss the limitations associated with studying some of these mice and how transgenic mouse models have contributed to the development of therapeutics for the treatment of Alzheimer's disease.
Authors:
Donna M Wilcock
Related Documents :
20216546 - Traumatic brain injury and amyloid-β pathology: a link to alzheimer's disease?
18289026 - Alzheimer disease and the role of free radicals in the pathogenesis of the disease.
11886576 - Plasmapheresis in the dysproteinemias.
20371996 - development of anti-alzheimer's disease drug based on beta-amyloid hypothesis
24926196 - Disease progression model for clinical dementia rating-sum of boxes in mild cognitive i...
19519506 - D-serine regulation: a possible therapeutic approach for central nervous diseases and c...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  CNS & neurological disorders drug targets     Volume:  9     ISSN:  1996-3181     ISO Abbreviation:  CNS Neurol Disord Drug Targets     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-04     Completed Date:  2010-11-09     Revised Date:  2010-11-29    
Medline Journal Info:
Nlm Unique ID:  101269155     Medline TA:  CNS Neurol Disord Drug Targets     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  386-94     Citation Subset:  IM    
Affiliation:
Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA. donna.wilcock@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alzheimer Disease / drug therapy,  metabolism,  pathology*
Amyloid beta-Peptides / metabolism
Animals
Disease Models, Animal*
Mice
Mice, Transgenic* / genetics
Neurofibrillary Tangles / metabolism,  pathology
Neurons / pathology
Plaque, Amyloid / metabolism,  pathology
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeuti...
Next Document:  Antidiabetic medicinal plants as a source of alpha glucosidase inhibitors.